Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : Says Keytruda Met Primary Endpoint of Overall Survival in Patients With Liver Cancer

09/27/2021 | 07:57am EDT


ę MT Newswires 2021
All news about MERCK & CO., INC.
02:17pASTRAZENECA : Daiichi Sankyo in Clinical Trial Collaboration to Evaluate Datopotamab Derux..
MT
01:55pHealth Care Stocks Higher in Monday Trading Amid Large Gains by Biotechs
MT
09:41aXERIS BIOPHARMA : Merck in Collaboration Deal With Option to License ' XeriJect - Shares J..
MT
09:30aMERCK : Reports Positive Results From Phase 3 Trials Evaluating Combination HIV-1 Therapy
MT
09:14aHealth Care Stocks Mixed Premarket Monday
MT
07:27aMERCK : European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as..
AQ
07:13aMERCK : EU Medicines Regulator Starts Rolling Review For Merck And Co.'s COVID-19 Drug
MT
06:47aMERCK : Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investi..
BU
06:04aEVAXION BIOTECH A/S : Enters Deal With Merck to Test Cancer Drug Candidate Combination in ..
MT
06:01aMERCK : and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Ag..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 248 M - -
Net income 2021 13 308 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 17,2x
Yield 2021 3,17%
Capitalization 207 B 207 B -
EV / Sales 2021 4,65x
EV / Sales 2022 4,08x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 81,66 $
Average target price 94,79 $
Spread / Average Target 16,1%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-0.79%205 421
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979